Pyxis Oncology raises $50M upfront in private placement; warrants could add $64M

Pyxis Oncology, Inc.

Gross proceeds of ~$50M from 19.6M shares at $2.551/share; warrants at $3.289 for additional ~$64M if exercised.
Financing led by BVF Partners with GordonMD, RTW Investments, Coastlands Capital; expected close July 2, 2026.
Proceeds extend cash runway into Q2 2027; support MICVO Phase 1 monotherapy and Phase 1/2 combination studies.
Updated Phase 1 monotherapy data for 2L+ R/M HNSCC expected Fall 2026; Phase 1/2 combo data in Q4 2026.
Warrants exercisable upon earlier of public disclosure of MICVO Phase 1 data or Oct 1, 2026; expire July 2, 2029.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.